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Background: Effective antiretroviral therapy reduces HIV-1 RNA levels, improves CD4 T-cell counts, and lowers the
risk of opportunistic infections and malignancies. Interleukin-2 (IL-2) has been shown to increase CD4 T-cell
numbers mainly by expanding CD4 cells and by prolonging their half-lives. HIV-infected patients previously
enrolled into A328 had been randomized to antiretroviral therapy (ART) alone or ART followed by IL-2. In A5051, 53
patients from A328 who had previously received IL-2 were allowed to continue IL-2 for an additional 80 weeks; 27
patients who had received ART alone received IL-2 for 80 weeks.
Results: The patients previously receiving IL-2 continued to have elevated CD4 levels with extended use of IL-2.
The prior ART-alone recipients had increases in CD4 levels to comparable levels as the prior IL-2 recipients (median
804 versus 847 cells/mm
3 at week 72; 60% versus 9% had >50% increase in A5051 to week 72, p < 0.001). Those
who had previously received IL-2 required fewer IL-2 cycles to maintain their CD4 T-cell counts compared to those
newly initiating IL-2. The treatments were well tolerated with no significant differences in toxicity or
discontinuations between those newly versus previously receiving IL-2. There were few clinical events observed.
Conclusions: Although sustained CD4 T-cell count increases were seen with IL-2 administration as in other studies,
the absence of clinical benefit in two recent randomized trials has demonstrated no apparent role for IL-2 as a
therapy in HIV disease.
Trial Registration: A5051 ClinicalTrials.gov Identifier: NCT00000923.
Background
In HIV infection, CD4 cell number progressively
decreases, predisposing affected individuals to the devel-
opment of opportunistic infections or malignancies if
they are left untreated. Effective antiretroviral therapy
reduces HIV-1 RNA levels, improves CD4 counts, and
lowers the risk of opportunistic infections and malignan-
cies. Interleukin-2 (IL-2) has been shown to increase
CD4 T-cell numbers mainly by expanding CD4 cells
and by prolonging their half-lives [1-3].
AIDS Clinical Trial Group (ACTG) study A5051 was an
open-label study that explored continuation therapy with
IL-2 for patients who had participated in A328 [4]. A328
enrolled patients with little or no prior antiretroviral
experience and CD4 T cell counts between 50 and 350
cells/mm
3 who were then treated with a 12-week course
of protease inhibitor-containing antiretroviral therapy. If
their HIV-1 RNA was less than 5,000 copies/ml, they were
randomized to continue antiretroviral therapy (ART)
a l o n eo rw i t he i t h e rI Vo rs u b c u t a n e o u sI L - 2 .T h es t u d y
showed that IL-2 significantly expanded CD4 cell num-
bers, did not increase HIV-1 RNA levels and appeared to
reduce the number of AIDS-defining events [4].
The current study (A5051) was designed to investigate
the effects of continuing subcutaneous IL-2 in patients
receiving IL-2 in A328 and to determine the activity of
IL-2 in patients who had previously been treated with
antiretroviral therapy alone for 84 weeks.
Methods
Patients were eligible for A5051 if they had completed
≥84 weeks of A328 [4]. Those with prior IL-2 must have
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their A328 week 12 CD4 level (timepoint of IL-2 initia-
tion), and all patients had a plasma HIV RNA ≤5,000
copies/ml before the IL-2 phase of A5051. Patients who
received IV IL-2 in A328 were allowed to switch to sub-
cutaneous IL-2 during that study. Most patients pre-
viously treated with IL-2 had received subcutaneous
IL-2 prior to enrolling in A5051 [4].
Patients with >5,000 copies/ml of HIV-1 RNA or
those without prior IL-2 who had HIV-1 RNA ≤5,000
copies/ml could change their antiretroviral regimen and
then begin IL-2 after documenting HIV RNA ≤5,000
copies/ml. Subjects were then followed for 80 weeks. All
subjects provided written informed consent and the
study was approved by the institutional review boards of
each participating site.
The primary objective was to determine the long-term
safety and efficacy of IL-2 in maintaining or increasing
CD4 T-cell counts in patients who had previously been
in A328. Other objectives were to describe the effect of
IL-2 on virologic breakthrough, to examine the durabil-
ity of immunologic changes on long term IL-2, and to
determine if there were differences in those that started
on IL-2 after 84 weeks of antiretrovirals alone as com-
pared to those begun after 12 weeks of ART.
CD4 and CD8 T-cell counts were measured every 8
weeks during the 80-week trial. HIV-1 RNA testing was
performed at an ACTG certified laboratory every 24
weeks. Routine hematology and chemistries were per-
formed prior to and at day 5 and 30 of each IL-2 cycle.
Pregnancy tests were performed on female patients
2 weeks prior to entry and 2 weeks before each cycle. A
skin test battery consisting of PPD (Connaught), tetanus
toxoid (Connaught) mumps (Connaught) and candida
albicans (ALK laboratories) was performed every 24
weeks.
An immunology substudy measured advanced flow
markers and lymphoproliferation responses at cycle 2, 4,
7 and at the time of the final evaluation using ACTG
consensus methods that used fluorochrome-labeled
monoclonal antibodies to CD3, CD4, CD8, CD45RA,
CD62L, CD38 and HLA-DR. Proliferation responses
were measured to phytohemaglutenin (PHA), tetanus
toxoid, candida and HIV antigens using ACTG consen-
sus methods.
IL-2 was administered at 4.5 million units SC BID for
5 days every 8 weeks for the first three cycles for
patients without prior IL-2. Subsequent cycles could be
extended by 8-week increments for a maximum of 24
weeks as long as CD4 counts were >500 cells/mm
3.T h e
dose could be reduced to 2.5 million units twice daily at
the subsequent cycle if IL-2 was interrupted due to toxi-
city or intolerability. Patients with prior IL-2 were admi-
nistered IL-2 at 4.5 million units SC BID (or 2.5 million
units BID if reduced to this level in A328) every
8 weeks. Starting with the first cycle, longer intervals
were allowed if the CD4 T-cell count stayed above
500 cells/mm
3.
The primary efficacy endpoint of A5051 was a CD4
cell count after 48 or 72 weeks that was 50% above the
CD4 cell count at A5051 baseline, comparing those
newly receiving IL-2 versus prior IL-2 recipients. Fisher’s
exact test compared proportions. For ordinal and con-
tinuous variables, the Wilcoxon rank-sum test was used.
The log-rank test compared time-to-event data.
Results
Eighty-one patients enrolled into A5051; 80 directly into
the IL-2 phase and one after a change in antiretroviral
regimen. One patient admitted to not taking antiretro-
virals during A328 and was excluded from efficacy ana-
lyses, but was included for the toxicity assessment.
Patients enrolled from 19 sites between April 1999 and
November 2000; 28 patients enrolled in the immunology
substudy. For the efficacy analysis, 27 of 52 (52%)
patients in the ART-only arm of A328 enrolled. Com-
parable percentages of those with prior IL-2 enrolled,
with 28 of 53 (53%) patients randomized in A328 to
i n t r a v e n o u sI L - 2e n r o l l i n ga n d2 5o f5 4( 4 6 % )o f
patients randomized in A328 to subcutaneous IL-2.
The median age was 40 (25
th -7 5
th percentiles: 35-48).
There were only 4 women; 47 were white non-Hispanic,
16 were black non-Hispanic, 14 were Hispanic and 3
were Asian, Pacific Islander or American Indian. The
median baseline CD4 T cell counts were 832 (595-1320)
and 466 (367-592) cells/mm
3 for patients with and with-
out prior IL-2, respectively. Previously IL-2-treated sub-
jects had greater increases from A328 week 12 to A5051
baseline in total lymphocyte counts (p < 0.001), CD4 T
cell counts (p < 0.001), CD8 T cell counts (p < 0.017)
and CD4 T cell percentage (p < 0.001).
The majority of patients 65/80 (81%) completed the
study; six were lost to follow-up, one died (cause of
death unknown), and three without prior IL-2 discontin-
ued the study due to IL-2-related side effects. The
majority of patients (83%) were on stavudine, lamivudine
and indinavir (n = 47) or zidovudine, lamivudine and
i n d i n a v i r( n=1 9 ) ;t h eo t h e rr e g i m e n sw e r es t a v u d i n e /
didanosine/indinavir (n = 5), zidovudine/didanosine/
indinavir (n = 1), stavudine/didanosine/indinavir/
nevirapine (n = 1), stavudine/didanosine/nelfinavir (n =
3), stavudine/lamivudine/nelfinavir (n = 2), abacavir/
efavirenz/nelfinavir (n = 1) and zidovudine/lamivudine/
nelfinavir/nevirapine (n = 1). Most patients (64/80, 80%)
completed study treatment (81% and 78%, for those
with and without prior IL-2) and no significant differ-
ence was seen between the groups in the time to treat-
ment discontinuation (p = 0.96).
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least one cycle of therapy; one patient with previous
IL-2 never met the criteria for starting IL-2 (CD4 count
≤500 cells/mm
3). The median total dose was 45 million
international units for all cycles. Previously IL-2-treated
patients had longer times between cycles because they
did not meet the CD4 criterion for a subsequent cycle,
resulting in a median (25
th-75
th percentiles) of 5 (3-7)
cycles for patients without prior IL-2, and 4 (3-5) cycles
for patients with prior IL-2. In patients without prior
IL-2, 16/27 (59%) received ≥5 cycles versus 18/53 (34%)
patients with prior IL-2.
More occurrences of grade ≥3 signs/symptoms and
grade ≥3 or higher laboratory abnormalities were seen
in those newly receiving IL-2, but differences were not
statistically significant (p = 0.13 and p = 0.072). There
was only one AIDS-defining event which was Kaposi’s
sarcoma diagnosed at week 32 and only one HIV-related
event, oral hairy leukoplakia at week 42, both in patients
with prior IL-2.
There were significant differences in the primary end-
point. In those newly receiving IL-2, 12/22 (55%) had
50% increases in CD4 count at week 48 and 12/20
(60%) at week 72, compared to 2/50 (4%, p < 0.001) and
4/47 (9%, p < 0.001) in those with prior IL-2. Prior IL-2
recipients started with higher CD4 counts and main-
tained these levels, in comparison to those newly receiv-
ing IL-2 whose CD4 counts increased and attained
comparable levels at week 72 (median 847 versus 804
cells/mm
3, 74% versus 90% ≥ 500 cells/mm
3; Figure 1).
There was no evidence of increased virologic break-
through, defined as two consecutive HIV-1 RNA levels
≥5000 copies/ml. Three subjects, all previously
IL-2-treated, met this criterion; two had pre-study HIV-
1 RNA levels between 3000 and 4500 copies/ml and one
had <50 copies/ml. Among 64 subjects who entered
with HIV-1 RNA <75 copies/ml, four subsequently had
two consecutive measurements ≥ 1000 copies/ml (two
subjects with and two without prior IL-2).
Skin test reactivity was examined by the number of
positive responses (induration ≥10 mm). At week 48,
more positive responses were seen in those newly
receiving IL-2 (4/8 versus 1/19 with ≥2p o s i t i v e
responses, p = 0.046, analyzing those with data for all
four antigens) although this was not confirmed at week
72 (2/8 versus 2/16, p = 0.96).
In the immunology substudy, there were no significant
differences in LPA responses to the tested antigens
between patients newly versus previously receiving IL-2
(p > 0.5 at both week 48 and 72).
Despite small sample sizes, longitudinal assessment of
CD4 and CD8 subsets showed that the number of naive
(CD45RA+/CD62L+) CD4 cells rose gradually in both
groups during A328 and A5051 (Figure 2). Memory (non-
naïve) CD4 counts increased in response to IL-2 in
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Figure 1 Median CD4 T cell counts over time for the participants in A5051. The ‘Previous IL-2’ group initiated IL-2 at week 12 of A328. The
‘No prior IL-2’ group initiated IL-2 in A5051. Vertical bars represent 25
th and 75
th percentiles.
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increase after IL-2 in A5051. The prior IL-2 recipients
maintained CD4 memory cells during A5051. There were
significant decreases in CD4 and CD8 activation markers
(% CD38+/HLA-DR+) during A328 in both the IL-2 and
antiretroviral-alone groups but little change during A5051.
Discussion
As a rollover trial to A328 [4], A5051 produced addi-
tional data on the long-term safety and efficacy of IL-2.
With regard to safety, the dosages utilized, which aver-
aged 4.5 million international units BID for 5-day cycles,
were relatively well tolerated. There was some increase
in both symptoms and laboratory abnormalities that
appeared to be higher in those receiving IL-2 for the
first time but these differences did not reach statistical
significance.
The side effect profile was actually better than
observed in A328 wherein the starting doses were
higher in both the IV groups and the subcutaneous
group. However, the majority of patients in that trial
had been reduced to the dosage utilized in A5051 and
had been switched to subcutaneous IL-2. Patients
who had received IL-2 in A328 tolerated its continua-
tion for the additional period in A5051, although A5051
may have selected for individuals better able to tolerate
IL-2. In those newly initiating IL-2, more than half
received ≥5 cycles. Overall, the data suggest that this
dosage is relatively well tolerated.
With regard to the primary endpoint, those newly
receiving IL-2 had a significantly greater likelihood of a
50% increase in CD4 T-cell counts at 48 and 72 weeks.
Previously IL-2-treated patients had continued, relatively
constant, higher CD4 T-cell counts which had been pre-
viously increased during A328. This may be due to a
form of homeostatic effect which keeps CD4 counts
induced by IL-2 within a finite range, preventing CD4
counts from going into a supernormal range. Patients
who had received IL-2 in A328 also had fewer cycles of
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Figure 2 Median CD4 and CD8 T cell subsets over time for the participants in A5051. (A) Naïve (CD45RA+/CD62L+) CD4 T-cell counts, (B)
Memory (non-naïve: CD45RA- or CD62L-) CD4 T cell counts, (C) Percentage activated (CD38+/HLA-DR+) CD4 T-cells and (D) Percentage activated
(CD38+/HLA-DR+) CD8 T-cells.
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increased the rate of virologic breakthrough as measured
by increases in HIV-1 RNA levels, consistent with other
studies showing viral suppression in 80-90% of patients
treated with IL-2 and ART, similar to those receiving
ART alone [4,5].
The advanced flow data suggests IL-2 has a greater
influence on CD4 memory T-cells in our study popula-
tion than on naive T-cells as has been reported [6]. The
influence of IL-2 is two-fold: memory cells are increased
in number and their longevity is prolonged [2,3]. The
lesser increase in naïve versus memory CD4 T-cells in
those newly receiving IL-2 in the present study may be
due to subjects’ prior immune reconstitution on ART
and their higher pre-IL-2 total CD4 T-cell counts (med-
ian 466 cells/mm
3) and naïve CD4 T-cell counts as
compared to earlier investigations (mean pre-IL-2 CD4
T-cell count: 300 cells/mm
3)[6]. Decreases were seen in
both CD4 T-cell and CD8 T-cell activation markers, but
patterns were similar for those first receiving IL-2 in
A328 versus A5051.
Although some evidence was seen that new receipt of
IL-2 enhanced skin test reactivity, the recent findings of
the ESPRIT and SILCAAT randomized trials showed no
clinical benefit from long-term IL-2 when added to anti-
retroviral therapy [5]. This is in contrast to A328 [4],
which showed an apparent decrease in AIDS-defining
and HIV-related infections in the IL-2 treated group.
Conclusions
T h i ss t u d ys h o w e dt h a ta sc o m p a r e dt oag r o u po f
patients that had tolerated and responded to treatment
with concurrent antiretroviral therapy and IL-2 in a pre-
vious study, patients newly exposed to IL-2 after initial
ART achieved similar CD4 T-cell numbers after 72
weeks. Median CD4 levels above 800 cells/mm
3 were
maintained in the previously IL-2 treated patients, with
fewer cycles than in those newly receiving IL-2. But
considering the two large randomized trials and their
findings that IL-2 therapy in HIV-infected patients
receiving antiretroviral therapy showed no clinical bene-
fit but higher rates of serious adverse events [5], these
studies do not support a role for IL-2 in HIV infection.
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